Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.

8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $5.00 to $16.00. On average, they expect the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 177.0% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.

Karyopharm Therapeutics' stock was trading at $3.40 at the start of the year. Since then, KPTI stock has decreased by 0.9% and is now trading at $3.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our KPTI earnings forecast.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The company had revenue of $37.69 million for the quarter, compared to the consensus estimate of $25.84 million. During the same quarter last year, the firm earned ($0.73) earnings per share.

Karyopharm Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $157.70 million-$157.70 million, compared to the consensus revenue estimate of $161.68 million.

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Birchview Capital LP (0.36%), Hennion & Walsh Asset Management Inc. (0.18%), Los Angeles Capital Management LLC (0.13%), New York State Common Retirement Fund (0.06%), Redwood Wealth Management Group LLC (0.04%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends.

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KPTI stock can currently be purchased for approximately $3.37.

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $273.48 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

The company employs 442 workers across the globe.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.